Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lomustine vs lomustine + bevacizumab in recurrent glioblastoma
2024-519437-27-02Phase 3Authorised
- Sponsor
- Rigshospitalet
- Start
- Jan 2025
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial in glioblastoma (GBM) comparing Lomustine monotherapy with Lomustine + bevacizumab (2 arms). Primary endpoint: Overall survival. Planned start Jan 2025; status: authorised.
02
Drugs
lomustinebevacizumab-bvzr
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2024-519437-27-02.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519437-27-02.